Amid a surge of RSV, hope for new vaccines. As many as four new RSV vaccine candidates could soon be sent for review by the U.S. Food and Drug Administration, experts say, and dozens more are in testing or under development. Read more
MONDAY, Nov. 7, 2022 (HealthDay News) — Infants and children sick with RSV are flooding pediatricians’ offices and children’s hospitals across the United States, due to an early surge of the common childhood virus this year.
Is surgery always necessary for chronic chest pain? A new clinical trial finds patients’ overall risk of death is about the same whether they choose aggressive surgical treatment or a more conservative approach focused on medication and lifestyle changes. Read more
MONDAY, Nov. 7, 2022 (HealthDay News) — Folks suffering chest pain from clogged arteries appear to have some true flexibility in choosing the medical care that’s right for them, researchers report.
Paxlovid might cut odds for long COVID. A new analysis showed people treated with the drug had a 26% reduced risk of developing several long COVID conditions, including heart disease, blood disorders, fatigue and other issues. Read more
People are also reading…
MONDAY, Nov. 7, 2022 (HealthDay News) — The antiviral pill Paxlovid not only reduces hospitalization and death after catching COVID-19: New research shows it also cuts the chances of long COVID by roughly 25%.
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
